Cancer/Tumors Clinical Trials

A listing of Cancer/Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

RATIONALE: Vaccines made from DNA or a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the cervix may be an …

human papilloma virus vaccine
cervical intraepithelial neoplasia
adenocarcinoma
measurable disease
primary cancer
  • 55 views
  • 25 Jan, 2021
  • 1 location
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

tools that will map disease extent in HG EOC. A recent study has shown that at immunohistochemistry GCP=II is overexpressed in ovarian cancer tumors, both primary and metastatic. Glucose

tumor markers
carcinoma
ovarian epithelial cancer
tumor debulking
ovarian epithelial carcinoma
  • 0 views
  • 10 Apr, 2021
  • 1 location
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

surgery (neoadjuvant), both anastrozole and letrozole have been shown to successfully shrink breast cancer tumors in most patients. In over 50% of patients, anastrozole and letrozole when given for about

estrogen
core needle biopsy
estrogen receptor
primary tumor
erbb2
  • 19 views
  • 23 Jan, 2021
  • 1 location
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

PARP inhibitors have changed the treatment paradigm of ovarian cancer. Most patients using PARP(poly-ADP ribose polymerase) inhibitors will suffer different grades of adverse events(AEs), followed by dose reduction. It has not been reported whether the dose-reduced olaparib as maintenance treatment have an impact on efficacy. Both PAOLA-1 and AVANOVA 2 …

cancer of the ovary
peritoneal cancer
fallopian tube
ovarian cancer
KIT
  • 5 views
  • 27 Jan, 2021
  • 1 location
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits tumor angiogenesis and is also recommended for the treatment of recurrent ovarian cancer. Clinical …

cancer of the ovary
peritoneal cancer
fallopian tube
niraparib
ovarian cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor

The investigators will perform this study to prospectively compare the clinical outcome after percutaneous microwave ablation(MWA) and breast conserving surgery of benign and malignant breast lesion under ultrasound (US) guidance.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy. This study evaluates whether or not the addition of simvastatin to the dual anti-HER2 therapy regimen helps make the tumor respond to the anti-HER2 therapy again. All participants will receive simvastatin …

adenocarcinoma
metastasis
platelet count
measurable disease
endocrine therapy
  • 6 views
  • 24 Jan, 2021
  • 2 locations
Dotarem vs Gadobutrol Contrast for Breast MRI

In this randomized clinical trial, the investigators expect to demonstrate that the MRI contrast agent Dotarem is not less effective in contrast enhancement of breast lesions then Gadavist. Participants will be randomized to receive either Dotarem or Gadavist. In all cases, inclusion criteria will require patients having undergone or scheduled …

  • 0 views
  • 30 Apr, 2021
  • 1 location
Nivolumab Ipilimumab and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and …

her2/neu-negative breast cancer
metastasis
HER2
triple negative breast cancer
measurable disease
  • 0 views
  • 25 Jan, 2021
  • 1 location
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk …

  • 0 views
  • 27 Jan, 2021
  • 1 location